A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.

James R. Berenson, Sal Bevivino, Russell Mapes et al.|Blood|2005

Cited by 11